NYSE American - Nasdaq Real Time Price USD

Calidi Biotherapeutics, Inc. (CLDI)

0.7001 +0.0211 (+3.11%)

At close: November 6 at 3:19:24 PM EST

0.7681 +0.0881 (+12.96%)

Pre-Market: 7:43:11 AM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories

GlobeNewswire 13d ago

CLDI
+12.96%
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026

GlobeNewswire 21d ago

CLDI
+12.96%
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

GlobeNewswire 1mo ago

CLDI
+12.96%
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire 2mo ago

CLDI
+12.96%
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire 2mo ago

CLDI
+12.96%
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

GlobeNewswire 3mo ago

CLDI
+12.96%
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

GlobeNewswire 3mo ago

CLDI
+12.96%
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

GlobeNewswire 4mo ago

CLDI
+12.96%
LEGN

RARE
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

GlobeNewswire 4mo ago

CLDI
+12.96%
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9

ACCESS Newswire 5mo ago

CLDI
+12.96%
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

GlobeNewswire 5mo ago

CLDI
+12.96%
Calidi Biotherapeutics Provides Required NYSE American Disclosure

GlobeNewswire 5mo ago

CLDI
+12.96%

Performance Overview

Return	CLDI	S&P 500 (^GSPC)
YTD	-96.26%	+7.76%
1-Year	-97.36%	+9.77%
3-Year	-99.98%	+68.96%

U.S. markets open in 1h 41m

Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories

Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

Calidi Biotherapeutics Provides Required NYSE American Disclosure